Fibrotic diseases partnership with Enleofen

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases  Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio  Boehringer Ingelheim aims to develop therapies for multiple fibrotic human disorders, including non-alcoholic steatohepatitis (NASH) and interstitial lung diseases (ILDs)Singapore-based Enleofen to receive in excess of one billion USD per product in upfront and success-based development and commercialization milestones
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news